 A STUDY OF LENVATINIB, A MULTI-TARGETED TYROSINE KINASE INHIBITOR, COMBINED WITH PEMBROLIZUMAB PD-1 INHIBITOR FOR THE TREATMENT OF METASTATIC GASTROESOPHAGEAL CANCER PATIENTS WHO HAVE PROGRESSED ON FIRST OR SUBSEQUENT LINE THERAPIES: 